Maureen Achebe goes into detail about the open label extension of the HOPE trial that evaluated to use of Voxelotor in patients with sickle
See more from Rare Disease Report
The HOPE trial open label extension continued to examine the efficacy and safety of voxelotor in patients with #SCD for 144 weeks and revealed promising results. Maureen Achebe, MD, MPH, discusses the details in an interview with @GiulianaGrossi. https://t.co/DHJ8s2NfoT - view on twitter